Education
About Us
Working with TipRanks
Follow Us
Sartorius AG (DE:SRT)
XETRA:SRT
Top Page
Sartorius
(XETRA:SRT)
Rating:69Neutral
Price Target:
€192.00
▲(7.26%Upside)
Sartorius (SRT) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€13.55B
Dividend Yield0.42%
Average Volume (3M)7.25K
Price to Earnings (P/E)126.8
Beta (1Y)1.51
Revenue Growth3.99%
EPS Growth-36.36%
CountryDE
Employees13,573
SectorHealthcare
Sector Strength39
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.22
Shares Outstanding37,440,000
10 Day Avg. Volume3,509
30 Day Avg. Volume7,252
Financial Highlights & Ratios
PEG Ratio10.40
Price to Book (P/B)4.41
Price to Sales (P/S)0.00
P/FCF Ratio19.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€250.00Price Target Upside39.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Sartorius Business Overview & Revenue Model
Company DescriptionSartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
How the Company Makes MoneySartorius AG generates revenue primarily through the sale of its bioprocess solutions and laboratory products. The Bioprocess Solutions division, which accounts for a significant portion of the company's revenue, sells equipment and technologies used in the production of biopharmaceuticals, such as filtration systems, cell culture media, and single-use bioreactors. The Lab Products & Services division provides laboratory instruments, consumables, and services that support research and quality control processes. Key revenue streams include direct sales to pharmaceutical and biotechnology companies, as well as partnerships with research institutions and industrial clients. The company's earnings are also supported by its global presence, which allows it to cater to a diverse customer base across various regions.
Sartorius Earnings Call Summary
Earnings Call Date:Apr 16, 2025
(Q1-2025)
| % Change Since: 10.90%|
Next Earnings Date:Jul 22, 2025
Earnings Call Sentiment Positive
The earnings call presented a strong start to 2025 with significant growth in consumables and margin expansion. However, challenges in equipment sales, particularly in the Lab Products & Services division, and potential impacts from tariffs were noted. The overall performance was positive, with strategic acquisitions and strong cash flow contributing to an optimistic outlook.Q1-2025 Updates
Positive Updates
Impressive Start to 2025
Sartorius reported a strong start to the fiscal year with a 6.5% sales revenue growth in constant currencies and a book-to-bill ratio above one for both divisions.
Double-Digit Growth in Consumables
The Bioprocess Solutions division saw a 10% revenue increase, driven by strong demand for consumables.
Significant Margin Expansion
Underlying EBITDA margin increased by 120 basis points to 29.8% due to scale effects, improved product mix, and efficiency programs.
Strong Cash Flow and Deleveraging
Operating cash flow tripled compared to the previous year, contributing to a reduction in the leverage ratio as planned.
Robust Regional Growth
The Americas region showed the strongest growth, with double-digit increases in the Bioprocess Solutions division.
MatTek Acquisition
Sartorius acquired MatTek, a leading provider of human cell-based microtissues and 3D models, for $80 million to enhance its advanced cell models portfolio.
Negative Updates
Challenges in Equipment Sales
The equipment business remains muted, impacting the Lab Products & Services division, which saw a sales decline of 5.5% in constant currencies.
Soft Demand in China
Sales in China were slightly below the previous year's Q1, contributing to challenges in the APAC region.
Potential Tariff Impacts
Concerns were raised about potential tariffs impacting cost structures, though mitigating measures are in place.
Company Guidance
In the first quarter of 2025, Sartorius AG and Sartorius Stedim Biotech reported a 6.5% sales revenue growth in constant currencies and a robust book-to-bill ratio above one. The Bioprocess Solutions division led the growth with a 10% increase in sales revenue, driven by strong double-digit growth in consumables, although equipment sales remained muted. The Lab Products & Services division faced challenges with a 5.5% decline in constant currencies due to soft equipment sales. The company announced its guidance for 2025, expecting approximately 6% sales revenue growth for the group, with an underlying EBITDA margin of 29% to 30%. Sartorius also highlighted a strategic acquisition of MatTek, enhancing its portfolio in advanced cell models, and discussed measures to address tariffs, aiming to maintain competitive positioning without impacting EBITDA margins.Sartorius Financial Statement Overview
Summary
Sartorius demonstrates strong cash flow generation and operational efficiency. However, profitability pressures and high leverage pose potential risks. The company should focus on improving cost management and reducing debt levels to enhance financial stability and performance.Income Statement
Sartorius shows moderate revenue growth with a slight increase in TTM (Trailing-Twelve-Months) revenue compared to the previous annual period. However, the gross profit margin and net profit margin have weakened over the periods, indicating pressure on cost management and profitability. The EBIT and EBITDA margins suggest operational efficiency, but the declining net income is a concern.65
Positive
Balance Sheet
The company's balance sheet reflects a stable financial structure with reasonable equity levels relative to assets. However, the debt-to-equity ratio is elevated, signaling potential leverage risks. Despite this, the return on equity remains positive, indicating effective use of shareholder funds.70
Positive
Cash Flow
Sartorius exhibits strong cash flow generation capabilities, with consistent operating cash flow and positive free cash flow. The free cash flow growth is encouraging, though capital expenditure levels have been high. The operating cash flow to net income ratio indicates solid cash conversion efficiency.72
Positive
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.44B | 3.38B | 3.40B | 4.17B | 3.45B | 2.34B |
| Gross Profit | 1.56B | 1.52B | 1.57B | 2.20B | 1.84B | 1.21B |
| EBITDA | 831.60M | 786.80M | 873.10M | 1.54B | 945.12M | 662.13M |
| Net Income | 125.10M | 84.00M | 205.20M | 913.10M | 426.98M | 321.47M |
Balance Sheet | ||||||
| Total Assets | 10.11B | 10.10B | 9.76B | 6.98B | 5.70B | 4.70B |
| Cash, Cash Equivalents and Short-Term Investments | 877.10M | 828.70M | 394.20M | 196.80M | 360.99M | 217.65M |
| Total Debt | 4.63B | 4.56B | 5.31B | 2.54B | 2.08B | 2.09B |
| Total Liabilities | 6.27B | 6.21B | 7.00B | 4.32B | 3.98B | 3.30B |
| Stockholders Equity | 2.71B | 2.76B | 2.07B | 1.99B | 1.26B | 1.05B |
Cash Flow | ||||||
| Free Cash Flow | 687.30M | 566.30M | 293.90M | 211.60M | 458.65M | 271.27M |
| Operating Cash Flow | 1.04B | 976.20M | 853.60M | 734.20M | 865.81M | 511.52M |
| Investing Cash Flow | -374.40M | -425.80M | -2.82B | -1.13B | -569.61M | -1.27B |
| Financing Cash Flow | -944.30M | -128.30M | 2.17B | 209.90M | -165.18M | 907.47M |
Sartorius Technical Analysis
Negative
179.00
Price Trends
177.60
Negative
178.37
Negative
183.23
Negative
Market Momentum
1.18
Negative
50.50
Neutral
62.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:SRT, the sentiment is Negative. The current price of 179 is above the 20-day moving average (MA) of 173.63, above the 50-day MA of 177.60, and below the 200-day MA of 183.23, indicating a neutral trend. The MACD of 1.18 indicates Negative momentum. The RSI at 50.50 is Neutral, neither overbought nor oversold. The STOCH value of 62.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:SRT.
Sartorius Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | €13.55B | 126.80 | 3.55% | 0.42% | 3.99% | -36.36% | |
52 Neutral | $7.45B | 0.27 | -61.87% | 2.30% | 16.62% | 1.04% | |
| €4.69B | 29.59 | 7.48% | 1.15% | ― | ― | ||
| €14.07B | 22.75 | 4.37% | 3.00% | ― | ― | ||
| €23.66B | 56.85 | 6.28% | 2.03% | ― | ― | ||
| €47.54B | 16.87 | 9.74% | 2.01% | ― | ― | ||
| $60.94B | 27.52 | 11.14% | 1.79% | ― | ― |
* Healthcare Sector Average
Performance Comparison
DE:SRT
Sartorius
179.00
-3.23
-1.77%
GB:0DHC
Carl Zeiss Meditec
52.40
-11.25
-17.67%
GB:0H9X
Fresenius Medical Care AG & Co. KGaA
47.18
11.95
33.92%
GB:0OO9
Fresenius SE & Co. KGaA
41.99
12.95
44.59%
GB:0O14
Merck KGaA
111.60
-33.99
-23.35%
SEMHF
Siemens Healthineers AG
56.15
-0.97
-1.70%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.